Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
kg, kg · 1 trial · 2 indications
Plasma decay half-life is the time measured for the plasma concentration of PF-04950615 to decrease by one half.
CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
AUCtau was the AUC from time 0 to the end of the dosing interval, where the dosing interval was 12 hours.
Plasma decay half-life is the time measured for the plasma concentration of atorvastatin to decrease by one half.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
| Arm | Type | Description |
|---|---|---|
| PF-04950615 (RN316) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 4 mg/kg | BIOLOGICAL | RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes. |
| 0.5 mg/kg | BIOLOGICAL | RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes. |
Inclusion Criteria: * On stable doses of atorvastatin (40 mg daily) for 45 days prior to Day 1. * BMI 18.5 to 40 kg/m2 inclusive, and body weight equal or lower than 150 kg. Exclusion Criteria: * History of a cardiovascular event (e.g., MI ) during the past year. * Poorly controlled Type 1 or Typ...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. | ARWR | 7 | PHASE3 | zodasiran, Plozasiran |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Inclisiran, Pelacarsen, DII235 |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Enlicitide |
| AstraZeneca PLC | AZN | 1 | PHASE3 | AZD0780 |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | Olezarsen |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE2 | Alirocumab |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Solbinsiran |
| MediciNova, Inc. | MNOV | 1 | PHASE2 | MN-001 |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE1 | Obicetrapib |
| Verve Therapeutics, Inc. | VERV | 3 | PHASE1 | VERVE-102, VERVE-201 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| Esperion Therapeutics, Inc. | ESPR | 1 | - | Bempedoic acid+ Ezetimibe |
1 mg, 5 mg, 10 mg is an investigational drug being studied for use in meningococcal vaccine, non-Hodgkin lymphoma, growth disorder, acute otitis media, hypogonadism, and healthy volunteers. It is currently in Phase 1 clinical development.
1 mg, 5 mg, 10 mg is being developed by Pfizer, Inc. (NYSE: PFE). The drug is currently in Phase 1 clinical development.
1 mg, 5 mg, 10 mg is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
1 mg, 5 mg, 10 mg has been studied in clinical trials including NCT00037791, NCT00039910, NCT00174421, and NCT01163851. These trials have investigated its use in conditions such as thrombocytopenia, non-Hodgkin lymphoma, growth disorder, and hypercholesterolemia.
1 mg, 5 mg, 10 mg is also known as PN-152,243 and PN-196,444 in clinical trials. These names refer to the same investigational drug being developed by Pfizer.